Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype-guided doses in renal transplantation patients.

Sirirat AnutrakulchaiCholatip PongskulKittrawee KritmetapakChulaporn LimwattananonSuda Vannaprasaht

Published in: British journal of clinical pharmacology (2019)

Determination of the CYP3A5 genotype improved therapeutic range achievement. CYP3A5*1/*1 patients who have high risks of DGF should be closely monitored because of an increased risk of DGF and reduced glomerular filtration rate with high tacrolimus doses.

Keyphrases

end stage renal disease
chronic kidney disease
newly diagnosed
prognostic factors
climate change
patient reported outcomes
high resolution
patient reported
human health